$20.42
0.34% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

MediWound Ltd. Stock price

$20.42
+0.50 2.51% 1M
+3.13 18.10% 6M
+2.62 14.72% YTD
+4.81 30.81% 1Y
+6.77 49.60% 5Y
-29.98 59.48% 10Y
-100.47 83.11% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.07 0.34%
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

Key metrics

Market capitalization $219.94m
Enterprise Value $188.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.79
P/S ratio (TTM) P/S ratio 11.45
P/B ratio (TTM) P/B ratio 7.32
Revenue growth (TTM) Revenue growth -3.22%
Revenue (TTM) Revenue $19.21m
EBIT (operating result TTM) EBIT $-20.89m
Free Cash Flow (TTM) Free Cash Flow $-19.10m
Cash position $38.27m
EPS (TTM) EPS $-1.96
P/E forward negative
P/S forward 9.20
EV/Sales forward 7.86
Short interest 10.37%
Show more

Is MediWound Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

MediWound Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a MediWound Ltd. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a MediWound Ltd. forecast:

Buy
100%

Financial data from MediWound Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
19 19
3% 3%
100%
- Direct Costs 16 16
0% 0%
86%
2.77 2.77
18% 18%
14%
- Selling and Administrative Expenses 13 13
17% 17%
69%
- Research and Development Expense 10 10
51% 51%
54%
-19 -19
46% 46%
-101%
- Depreciation and Amortization 1.47 1.47
7% 7%
8%
EBIT (Operating Income) EBIT -21 -21
42% 42%
-109%
Net Profit -21 -21
66% 66%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about MediWound Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediWound Ltd. Stock News

Neutral
Seeking Alpha
23 days ago
MediWound Ltd. (NASDAQ:MDWD ) Q1 2025 Earnings Conference Call May 21, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Ofer Gonen - CEO Hani Luxenburg - CFO Barry Wolfenson - EVP of Strategy and Corporate Development Conference Call Participants Chase Knickerbocker - Craig-Hallum RK - H.C.
Neutral
GlobeNewsWire
24 days ago
VALUE Phase III trial of EscharEx ® in venous leg ulcers advancing as planned NexoBrid ® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MD...
Positive
Seeking Alpha
28 days ago
I rate MediWound a buy due to strong revenue growth, a robust pipeline, and significant undervaluation with massive upside potential. NexoBrid's commercial success and orphan drug status drive revenue growth, while EscharEx's promising phase 3 trial could unlock a huge chronic wound market. The company's strong balance sheet, with ample cash and minimal debt, provides a solid runway for R&D and...
More MediWound Ltd. News

Company Profile

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Head office Israel
CEO Ofer Gonen
Employees 111
Founded 2000
Website www.mediwound.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today